New drug combo trial aims to boost lymphoma survival
NCT ID NCT07299331
Summary
This study is testing a combination of three medications—zanubrutinib, rituximab, and lenalidomide—as the first treatment for adults with advanced marginal zone lymphoma, a type of blood cancer. Researchers want to see if this combination helps patients live longer and controls the disease better than standard treatments, while carefully tracking any side effects. About 50 participants will take the drugs as directed and visit the clinic regularly for check-ups and tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.